Related Experiment Videos
Gatifloxacin: a new fluoroquinolone
1Department of Clinical Microbiology, Royal University Hospital, 103 Hospital Drive, Saskatoon, Saskatchewan, S7N 0W8, Canada. blondeauj@sdh.sk.ca
Expert Opinion on Investigational Drugs
|November 4, 2000
Summary
Gatifloxacin, a novel fluoroquinolone antibiotic, demonstrates potent activity against common respiratory pathogens and atypical bacteria. Clinical trials support its efficacy in treating various infections with a favorable safety profile.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Gatifloxacin is an 8-methoxy-fluoroquinolone antimicrobial agent.
- It exhibits enhanced activity against Gram-positive and atypical pathogens, alongside broad-spectrum Gram-negative coverage.
Purpose of the Study:
- To evaluate the antimicrobial spectrum and clinical utility of gatifloxacin.
- To assess its efficacy in treating respiratory tract, urinary tract, and skin infections.
Main Methods:
- MIC(90) values were determined for various bacterial pathogens.
- Clinical trial data was analyzed for efficacy and safety.
Main Results:
- Gatifloxacin showed potent activity (MIC(90) <= 0.5 microg/ml) against key respiratory pathogens like Streptococcus pneumoniae and Haemophilus influenzae.
- It demonstrated bactericidal activity and a post-antibiotic effect.
- Clinical trials supported its use for respiratory, urinary, and skin infections.
Conclusions:
- Gatifloxacin is a promising antimicrobial agent with broad-spectrum activity and a low propensity for resistance development.
- Its efficacy and safety profile make it a viable option for treating common bacterial infections.